The guidance assumes 2022 non -COVID revenues at mid-point of guidance, or about $44B, and 2022-2025 compound annual growth rate of 6% and excludes 2022-2025 business development, or BD. Pfizer sees 2030 potential non-COVID revenues at different CAGR rates of about $84B assuming a 2025-203 CAGR of 10% and about $70B assuming a 2025-2030 CAGR of 6%, slides for the company’s Fireside Chat at the 41st Annual J.P. Morgan Healthcare Conference stated. See Insiders’ Hot Stocks on TipRanks >>
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Read More on PFE:
- Moderna considering $110-$130 for COVID shot, similar to Pfizer’s, WSJ says
- Pfizer in talks to license Chinese drugmakers for generic Paxlovid, Reuters says
- Pfizer: FDA accepts for priority review sBLA for 20vPnC
- Morgan Stanley sees Moderna’s phase 3 RSV vaccine data as catalyst-driven idea
- 3D Systems appoints Bruce to Medical Advisory Board